ABSTRACT
Background: Helicobacter pylori [H. pylori] is the main cause of gastroduodenal diseases, such as chronic atrophic gastritis, gastric ulcer [GU], and duodenal ulcer [DU]. There is a close relationship between H. or/-specific factors and different gastroduodenal diseases. The aim of the present study was to clarify the roles of the plasticity region genes [jhp0940, jhp0945, and jhp0947] and the known genes of cagPAI [cagA and cage] in relation to GU and DU diseases
Materials and Methods: A total of 173 strains that were isolated from 114 patients with non-atrophic gastritis [NAG], 30 patients with DU, and 29 patients with GU were genotyped. Data were collected and analyzed using SPSS software version 19.
Results: The cagE gene had the highest frequency [69.4%] and jhp0945 had the least frequency [11.0%] among the genes. When GU was considered as a dependant factor in simple logistic regression analysis, no genotype correlation was found with risk for GU in Iran [p>0.05]. Statistical analysis showed that cagA+ and cagAV jhp0940+ genotypes were significantly associated with an increased risk of DU but not GU. The Odds ratios [95% CI] were 3.143 [1.120-8.817], and 7.250 [1.493-38.199], respectively
Conclusion: Given the high frequency of cagE, this gene could be a suitable marker for the presence of cagPAI in Iranian strains. cagA[+] and cagAV jhp0940+genotypes can be beneficial biomarkers for risk prediction of DU in Iran
ABSTRACT
Helicobacter pylori [H. pylori] is the most important pathogens with the ability to persist for decades in the stomach; and it is considered as the most common agent for gastric cancer
The development of disease depends on factors such as strain-specific bacterial constituents, host susceptibility and environmental cofactors
Eradication of H. pylori can not only remarkably reduce the risk of relapse of peptic ulcers but also decrease the risk of gastric cancer in infected individuals with no severe injury or malignant tumor. In most cases, the gastric MALT lymphoma can be completely treated by the eradication of H. pylori infection
The use of anti-H pylori or anti-cancer therapeutic peptides, may be an effective strategy for the prevention of gastric cancer
Therefore, this review was aimed to assess literature regarding H. pylori virulence factors associated with gastric cancer as well as new therapeutic methods based on peptides